Clinical TrailsEisai Unveils Breakthrough Etalanetug Data at CTAD 2025: Significant Reduct... Eisai Unveils Breakthrough Etalanetug Data at CTAD 2025: Significant Reduct... Read Post »
Clinical TrailsMerck Presents Promising First-in-Human Data for Alzheimer’s Candidates M... Merck Presents Promising First-in-Human Data for Alzheimer’s Candidates M... Read Post »
Clinical TrailsAbbVie’s Phase 3 ECLIPSE Study Shows Atogepant (AQUIPTA®) Superior t... AbbVie’s Phase 3 ECLIPSE Study Shows Atogepant (AQUIPTA®) Superior t... Read Post »
Clinical TrailsOral Mosnodenvir Pill’s Rocky Road: 60% Dengue Success in Phase 2a Tr... Oral Mosnodenvir Pill’s Rocky Road: 60% Dengue Success in Phase 2a Tr... Read Post »
Clinical Trails Health TidingsAlexion Advances ALXN2420 to Phase 2: PeptiDream Unlocks Acromegaly Milesto... Alexion Advances ALXN2420 to Phase 2: PeptiDream Unlocks Acromegaly Milesto... Read Post »
Clinical Trails New Drug ApprovalNovo Nordisk Files FDA sNDA for Wegovy 7.2 mg Higher Dose After 20.7% Weigh... Novo Nordisk Files FDA sNDA for Wegovy 7.2 mg Higher Dose After 20.7% Weigh... Read Post »
Clinical TrailsSarepta Receives FDA Approval to Begin ENDEAVOR Cohort 8 Investigating Enha... Sarepta Receives FDA Approval to Begin ENDEAVOR Cohort 8 Investigating Enha... Read Post »
Clinical TrailsNovo Nordisk’s Amycretin Phase 2 Trial Shows Up to 14.5% Weight Loss and ... Novo Nordisk’s Amycretin Phase 2 Trial Shows Up to 14.5% Weight Loss and ... Read Post »
Clinical TrailsJohnson & Johnson’s Posdinemab Fails to Meet Primary Endpoint in Auτ... Johnson & Johnson’s Posdinemab Fails to Meet Primary Endpoint in Auτ... Read Post »
Clinical TrailsKyowa Kirin Launches Phase 3 AOBA Study of KK8398 (Infigratinib) for Achond... Kyowa Kirin Launches Phase 3 AOBA Study of KK8398 (Infigratinib) for Achond... Read Post »
Clinical TrailsSarepta’s SRP-1003 siRNA Program Hits Key Enrollment Milestone, Triggers ... Sarepta’s SRP-1003 siRNA Program Hits Key Enrollment Milestone, Triggers ... Read Post »
Clinical TrailsNovo Nordisk’s Evoke Phase 3 Trial Fails to Show Semaglutide Benefit in A... Novo Nordisk’s Evoke Phase 3 Trial Fails to Show Semaglutide Benefit in A... Read Post »
Clinical TrailsNew Hope for Stroke Survivors: Bayer’s Asundexian Shows Promise in Reduci... New Hope for Stroke Survivors: Bayer’s Asundexian Shows Promise in Reduci... Read Post »
Clinical TrailsPfizer’s Next-Gen mRNA Flu Shot: A New Standard in Vaccine Innovation Pfizer’s Next-Gen mRNA Flu Shot: A New Standard in Vaccine Innovation Read Post »
Clinical TrailsAgios’ Mitapivat Delivers Positive Hemoglobin Gains but Mixed Pain‑Cr... Agios’ Mitapivat Delivers Positive Hemoglobin Gains but Mixed Pain‑Cr... Read Post »
Clinical TrailsMerck Announces Positive Topline Results from Pivotal Phase 3 Trial of Dora... Merck Announces Positive Topline Results from Pivotal Phase 3 Trial of Dora... Read Post »
Clinical TrailsNovo Nordisk’s Wegovy® (Semaglutide 2.4 mg) Delivers Liver Health Benefi... Novo Nordisk’s Wegovy® (Semaglutide 2.4 mg) Delivers Liver Health Benefi... Read Post »
Clinical TrailsLibrexia ACS Trial Ends Early as Efficacy Endpoint Not Met, BMS and J&J... Librexia ACS Trial Ends Early as Efficacy Endpoint Not Met, BMS and J&J... Read Post »
Clinical TrailsWINREVAIR Shows Promising Phase 2 Results in CpcPH with HFpEF WINREVAIR Shows Promising Phase 2 Results in CpcPH with HFpEF Read Post »
Clinical TrailsJohnson & Johnson’s TREMFYA® Confirms Unique Joint Protection in Pso... Johnson & Johnson’s TREMFYA® Confirms Unique Joint Protection in Pso... Read Post »
Clinical TrailsHow AUSTEDO and AUSTEDO XR Improve Quality of Life in Tardive Dyskinesia Pa... How AUSTEDO and AUSTEDO XR Improve Quality of Life in Tardive Dyskinesia Pa... Read Post »
Clinical TrailsVir Biotechnology’s Tobevibart & Elebsiran Combo Achieves Breakth... Vir Biotechnology’s Tobevibart & Elebsiran Combo Achieves Breakth... Read Post »
Clinical TrailsVertex Shows Promising Phase 1/2 Data for Povetacicept in IgA Nephropathy a... Vertex Shows Promising Phase 1/2 Data for Povetacicept in IgA Nephropathy a... Read Post »
Clinical TrailsGilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacap... Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacap... Read Post »
Clinical TrailsRegeneron Factor XI Antibodies Show Superior Efficacy for VTE PreventionÂ... Regeneron Factor XI Antibodies Show Superior Efficacy for VTE PreventionÂ... Read Post »
Clinical TrailsAmgen’s Repatha® Slashes First Major Cardiovascular Events Risk by 25% i... Amgen’s Repatha® Slashes First Major Cardiovascular Events Risk by 25% i... Read Post »
Clinical TrailsLivdelzi® (Seladelpar) Achieves New Milestone in PBC: Phase 3 Data Show La... Livdelzi® (Seladelpar) Achieves New Milestone in PBC: Phase 3 Data Show La... Read Post »
Clinical TrailsGanaplacide’s Innovative Discovery from 2.3 Million Molecules Yields ... Ganaplacide’s Innovative Discovery from 2.3 Million Molecules Yields ... Read Post »
Clinical TrailsAstraZeneca Baxdrostat Shows Breakthrough 14 mmHg 24-Hour Blood Pressure Re... AstraZeneca Baxdrostat Shows Breakthrough 14 mmHg 24-Hour Blood Pressure Re... Read Post »
Clinical TrailsHope for AFRS Sufferers: Dupixent’s Powerful Phase 3 Outcome Hope for AFRS Sufferers: Dupixent’s Powerful Phase 3 Outcome Read Post »
Clinical TrailsBayer’s Finerenone Significantly Reduces UACR in Adults with Chronic ... Bayer’s Finerenone Significantly Reduces UACR in Adults with Chronic ... Read Post »
Clinical TrailsFirst Oral PCSK9 Inhibitor from Merck Cuts LDL Cholesterol by 59% in HeFH P... First Oral PCSK9 Inhibitor from Merck Cuts LDL Cholesterol by 59% in HeFH P... Read Post »
Clinical TrailsRoche’s Fenebrutinib Achieves Groundbreaking Phase III Success as First O... Roche’s Fenebrutinib Achieves Groundbreaking Phase III Success as First O... Read Post »
Clinical TrailsAtacicept Achieves Breakthrough Phase 3 Results in Immunoglobulin A Nephrop... Atacicept Achieves Breakthrough Phase 3 Results in Immunoglobulin A Nephrop... Read Post »
Clinical TrailsEli Lilly’s Eloralintide Phase 2 Trial shows up to 20% Weight Loss with P... Eli Lilly’s Eloralintide Phase 2 Trial shows up to 20% Weight Loss with P... Read Post »
Clinical TrailsRoche’s Gazyva Shows Breakthrough Phase III Results in Idiopathic Nephrot... Roche’s Gazyva Shows Breakthrough Phase III Results in Idiopathic Nephrot... Read Post »
Clinical TrailsFDA Approves Rybelsus Oral Semaglutide for Cardiovascular Risk Reduction in... FDA Approves Rybelsus Oral Semaglutide for Cardiovascular Risk Reduction in... Read Post »
Clinical TrailsGefurulimab Symptom Relief in Myasthenia Gravis: PREVAIL Phase 3 Gefurulimab Symptom Relief in Myasthenia Gravis: PREVAIL Phase 3 Read Post »
Clinical TrailsNovartis Presents Positive Phase III NEPTUNUS-1 and NEPTUNUS-2 Trial Result... Novartis Presents Positive Phase III NEPTUNUS-1 and NEPTUNUS-2 Trial Result... Read Post »
Clinical TrailsBridgeBio Announces Positive Phase 3 CALIBRATE Trial Results for Encaleret ... BridgeBio Announces Positive Phase 3 CALIBRATE Trial Results for Encaleret ... Read Post »
Clinical TrailsIntellia Pauses Phase 3 CRISPR Trials after Life-Threatening Liver Injury i... Intellia Pauses Phase 3 CRISPR Trials after Life-Threatening Liver Injury i... Read Post »
Clinical TrailsSanofi’s Efdoralprin Alfa Achieves All Primary Endpoints in Phase 2 ElevA... Sanofi’s Efdoralprin Alfa Achieves All Primary Endpoints in Phase 2 ElevA... Read Post »
Clinical TrailsInnovent and Lilly’s Mazdutide Outperforms Semaglutide in Phase 3 DREAMS-... Innovent and Lilly’s Mazdutide Outperforms Semaglutide in Phase 3 DREAMS-... Read Post »
Clinical TrailsLong-Term SELECT Trial: Semaglutide Cuts Cardiovascular Events by 20% beyon... Long-Term SELECT Trial: Semaglutide Cuts Cardiovascular Events by 20% beyon... Read Post »
Clinical TrailsNipocalimab Delivers Breakthrough Efficacy and Safety in Sjögren’s Disea... Nipocalimab Delivers Breakthrough Efficacy and Safety in Sjögren’s Disea... Read Post »
Clinical TrailsAlector Faces Major Setback as Latozinemab Fails Phase 3 Trial, Cuts 50% St... Alector Faces Major Setback as Latozinemab Fails Phase 3 Trial, Cuts 50% St... Read Post »
Clinical TrailsModerna’s mRNA‑1647 CMV Vaccine Fails in Late‑Stage Trial, Showing On... Moderna’s mRNA‑1647 CMV Vaccine Fails in Late‑Stage Trial, Showing On... Read Post »
Clinical Trails ResearchFirst Successful Restoration of Central Vision in Dry AMD Using Subretinal ... First Successful Restoration of Central Vision in Dry AMD Using Subretinal ... Read Post »
Clinical TrailsNovo Nordisk’s Monlunabant Shows Promising Weight Loss and Metabolic Bene... Novo Nordisk’s Monlunabant Shows Promising Weight Loss and Metabolic Bene... Read Post »
Clinical TrailsHigher-Dose Semaglutide Achieves Historic 21% Weight Loss in Landmark STEP ... Higher-Dose Semaglutide Achieves Historic 21% Weight Loss in Landmark STEP ... Read Post »
